Overall survival nomogram for patients with spinal bone metastases (SBM)

Osong, Biche; Sanli, Ilknur; Willems, Paul; Wee, Leonard; Dekker, André; Lee, Seok Ho; Soest, Johan van

doi:10.1016/j.ctro.2021.02.010

Cited by 2 publications

(2 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Patients who met the following criteria were included: (1) patients were diagnosed with EC between 2010 and 2015, (2) EC was the primary malignant tumor, and (3) diagnosis was confirmed by histological biopsy. Patients were screened according to the exclusion criteria below: (1) unknown insurance status, (2) unknown race, (3) unknown marital status, (4) unclear primary site, (5) histological types other than adenocarcinoma (AC) and squamous cell carcinoma (SCC), ( 6) unknown grade, (7) unclear or unknown node (N) stage, (8) unknown BM, (9) unknown brain metastasis, (10) unknown liver metastasis, (11) unknown lung metastasis, (12) EC was not the first tumor. All patients were enrolled in the diagnostic cohort to determine risk factors for BM.…”

Section: Participantsmentioning

confidence: 99%

“…Globally, 316,000 new cases of EC are diagnosed each year with 286,000 deaths, while 13,000 new diagnoses and 12,600 deaths occur in the United States alone (2). The prognosis is poor, especially with metastatic disease (3)(4)(5). Patients with metastatic EC have a median survival time of only 6 months, and the 2-year survival rate is about 11.8% (6).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Predictive models for the risk and prognosis of bone metastasis in patients with newly-diagnosed esophageal cancer: A retrospective cohort study

Yuan

et al. 2023

Front. Surg.

View full text Add to dashboard Cite

BackgroundEsophageal cancer (EC) is a common malignant tumor worldwide, and patients with both EC and bone metastasis (BM) have a poor prognosis. We aimed to determine the risk and prognostic factors for BM in patients with newly diagnosed EC and to conduct two nomograms to predict the probability of BM and overall survival after BM.MethodsData from patients with EC from 2010 to 2015 were reviewed in the Surveillance, Epidemiology, and End Results (SEER) database. We divided participants into training and validation cohorts using univariate and multivariate logistic regression analyses and Cox regression models to explore the risk and prognostic factors of BM, respectively. Moreover, two nomograms were developed for predicting the risk and prognosis of BM in patients with EC. Then we used receiver operating characteristic curves, decision curve analysis, and calibration curves to evaluate the nomogram models. The overall survival of patients with EC and BM was analyzed using the Kaplan-Meier method.ResultsA total of 10,730 patients with EC were involved, 735 of whom had BM at the time of diagnosis. Histologic type, sex, age, N stage, primary site, liver, lung, and brain metastases, and tumor differentiation grade were identified as independent BM risk factors. Histological type, chemotherapy, brain, liver, and lung metastases were identified as prognostic risk factors for patients with EC and BM. We developed diagnostic and prognostic nomograms according to the results. Receiver operating characteristic curves, calibration, and Kaplan-Meier curves, and decision curve analysis all indicated that both nomograms had great clinical predictive ability and good clinical application potential.ConclusionsTwo novel nomograms were constructed to predict the risk and prognosis of BM in patients with EC. These prediction models can effectively assist clinicians in clinical decision-making based on their good accuracy and reliability.

show abstract

Section: Participantsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Predictive models for the risk and prognosis of bone metastasis in patients with newly-diagnosed esophageal cancer: A retrospective cohort study

Yuan

et al. 2023

Front. Surg.

View full text Add to dashboard Cite

show abstract

Monitoring and personalization in treatment of breast cancer patients with metastatic bone lesions

et al. 2022

View full text Add to dashboard Cite

The aim. To increase the efficiency of treatment of BC patients with metastatic lesions of long tubular bones by using, Multidetector computed tomography (MDCT) and bone marrow markers for diagnostics and monitoring the clinical course of the oncologic process, accompanied by surgical intervention with endoprosthetics along with the treatment of polymorbid pathology in a specific patient. Materials and methods. Authors provide systemic personification including visualization of the tumor site and its vascularization; printing out the 3D model; surgical planning, including optimal surgical access to the tumor site considering the volume and topographic and anatomical location and dissemination of the tumor, the convenience of intraoperative tasks (removal of the tumor, bone grafting or endoprosthetics), preoperative planning of bone resection lines with maximum preservation of intact bone tissue. Results. Personalization of the treatment of breast cancer patients with metastatic bone lesions contributes to a significant reduction in postoperative complications of endoprosthetic replacement of large joints (up to 15.2 %) and increases the overall three-year survival rate (up to 40.6 %), as well as significantly improves their quality of life. Conclusions. The personalization of treatment of patients with tumor lesions of the skeletons contributes to a significant decrease in the indicator of postoperative complications of endoprosthetics of great joints and to an increase in the total three-year survival rate, as well as to the improvement of the quality of life after the conducted treatment.

show abstract

Overall survival nomogram for patients with spinal bone metastases (SBM)

Cited by 2 publications

References 30 publications

Predictive models for the risk and prognosis of bone metastasis in patients with newly-diagnosed esophageal cancer: A retrospective cohort study

Predictive models for the risk and prognosis of bone metastasis in patients with newly-diagnosed esophageal cancer: A retrospective cohort study

Monitoring and personalization in treatment of breast cancer patients with metastatic bone lesions

Contact Info

Product

Resources

About